Len Blavatnik weighs big share purchase in Teva Pharma: Reports
Jerusalem: Billionaire businessman Len Blavatnik is looking to buy a significant stake in debt-ridden Israeli drugmaker Teva Pharmaceutical Industries Ltd, according to Israeli media reports.
Two of Israel’s leading financial news outlets, Globes and The Marker, reported on Sunday that Blavatnik has been examining a large share purchase in Teva, whose stock price hit a 17-year-low last week after the company again cut its annual profit forecast.
Officials at Blavatnik’s US-based industrial group, Access Industries, were not immediately reachable for comment. Teva, the world’s biggest generic drugs maker, declined to comment.
The Marker reported that Blavatnik was looking to acquire up to a $3 billion stake in Teva. The company has a $12.3 billion market cap.
The investment could either be done through a private stock listing, which would help Teva deal with its nearly $35 billion debt burden, or the shares could be bought from pharmaceutical firm Allergan, the report said.
Allergan received a 10% stake in Teva as part of a 2016 deal in which Teva bought its generics business for $40.5 billion. Allergan announced last week that it would begin selling down that stake.
Blavatnik’s Access has investments in real estate, chemicals, media and technology with Warner Music among its highest profile businesses. Reuters
- India’s GDP to reach $5 trillion by 2025: Top official at World Bank
- Petrol price hit highest level under BJP govt, diesel at record high
- Govt serious in bringing fugitive economic offenders to task: Rajnath Singh
- Sushma Swaraj arrives in China for talks with Wang Yi, SCO meet
- Make the best of technology to deal with administrative delays: Modi tells bureaucrats